Menu

ObsEva – $97 Million IPO

New York – February 16, 2017 – Cooley advised ObsEva on its $96.8 million initial public offering of 6,450,000 common shares. The underwriters maintain a 30-day option to purchase up to 967,500 additional common shares. The company now trades on the NASDAQ Global Select Market as “OBSV.”

ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Div Gupta  Partner New York
Charlie Kim  Partner San Diego, Los Angeles
Mark Ballantyne  Partner Reston
Natasha Leskovsek  Of Counsel Washington, DC
Phil Mitchell  Partner New York
Bill Christiansen  Partner Seattle
Barbara Mirza  Partner Los Angeles, Palo Alto
John McKenna  Partner Palo Alto
Paula Holland  Partner London
Helenanne Connolly  Partner Reston
Geoffrey Spolyar  Partner Boston
Related Practices & Industries

Life Sciences  Capital Markets  Public Companies